Title of article
Sustained efficacy up to 4•5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
Author/Authors
Diane M Harper، نويسنده , , Eduardo L Franco، نويسنده , , Cosette M Wheeler، نويسنده , , Anna-Barbara Moscicki، نويسنده , , Barbara Romanowski، نويسنده , , Cecilia M Roteli-Martins، نويسنده , , David Jenkins، نويسنده , , Anne Schuind، نويسنده , , Sue Ann Costa Clemens، نويسنده , , Gary Dubin ، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2006
Pages
9
From page
1247
To page
1255
Abstract
Background
Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. Our aim was to assess the long-term efficacy, immunogenicity, and safety of
Journal title
The Lancet
Serial Year
2006
Journal title
The Lancet
Record number
589520
Link To Document